Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.

Weiss GJ, Byron SA, Aldrich J, Sangal A, Barilla H, Kiefer JA, Carpten JD, Craig DW, Whitsett TG.

PLoS One. 2017 Jun 6;12(6):e0179170. doi: 10.1371/journal.pone.0179170. eCollection 2017.

2.

Differences in Host Innate Responses among Coccidioides Isolates in a Murine Model of Pulmonary Coccidioidomycosis.

Lewis ER, David VR, Doyle AL, Rajabi K, Kiefer JA, Pirrotte P, Barker BM.

Eukaryot Cell. 2015 Oct;14(10):1043-53. doi: 10.1128/EC.00122-15. Epub 2015 Aug 14.

3.

microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C.

Van Keuren-Jensen KR, Malenica I, Courtright AL, Ghaffari LT, Starr AP, Metpally RP, Beecroft TA, Carlson EW, Kiefer JA, Pockros PJ, Rakela J.

Liver Int. 2016 Mar;36(3):334-43. doi: 10.1111/liv.12919. Epub 2015 Sep 9.

4.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.

5.

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.

Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E.

Oncotarget. 2015 Apr 20;6(11):9073-85.

6.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

7.

Personalized treatment of S├ęzary syndrome by targeting a novel CTLA4:CD28 fusion.

Sekulic A, Liang WS, Tembe W, Izatt T, Kruglyak S, Kiefer JA, Cuyugan L, Zismann V, Legendre C, Pittelkow MR, Gohmann JJ, De Castro FR, Trent J, Carpten J, Craig DW, McDaniel TK.

Mol Genet Genomic Med. 2015 Mar;3(2):130-6. doi: 10.1002/mgg3.121. Epub 2014 Nov 27.

8.

Dexamethasone levels predict cortisol response after infant cardiopulmonary bypass.

Crow SS, Oliver WC Jr, Kiefer JA, Snyder MR, Dearani JA, Li Z, Burkhart HM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):475-81. doi: 10.1016/j.jtcvs.2013.09.023. Epub 2013 Nov 8.

9.

A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges.

Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Reiman R, Baker A, Marsh V, Von Hoff DD, Carpten JD, Craig DW.

PLoS One. 2013 Oct 30;8(10):e76438. doi: 10.1371/journal.pone.0076438. eCollection 2013.

10.

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.

Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.

11.

Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.

Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D.

PLoS One. 2012;7(10):e43192. doi: 10.1371/journal.pone.0043192. Epub 2012 Oct 10.

12.

Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy.

Baehner FL, Lee M, Demeure MJ, Bussey KJ, Kiefer JA, Barrett MT.

J Surg Oncol. 2011 May 1;103(6):563-73. doi: 10.1002/jso.21838. Review.

PMID:
21480251
13.

A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cells.

Arora S, Beaudry C, Bisanz KM, Sima C, Kiefer JA, Azorsa DO.

Assay Drug Dev Technol. 2010 Jun;8(3):295-320. doi: 10.1089/adt.2009.0240.

PMID:
20469965
14.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S.

J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43.

15.

Functional evidence implicating S100P in prostate cancer progression.

Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S.

Int J Cancer. 2008 Jul 15;123(2):330-339. doi: 10.1002/ijc.23447.

16.

Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, Corey E.

Neoplasia. 2006 Oct;8(10):862-78.

17.

Osteoprotegerin in prostate cancer bone metastasis.

Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL.

Cancer Res. 2005 Mar 1;65(5):1710-8.

18.

The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.

Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E.

Clin Exp Metastasis. 2004;21(5):381-7.

19.

Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer.

Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent JM, Carpten JD, Kallioniemi OP, Mousses S.

Nat Genet. 2004 Sep;36(9):979-83. Epub 2004 Aug 8.

PMID:
15300251
21.

Osteopontin: possible role in prostate cancer progression.

Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW.

Clin Cancer Res. 1999 Aug;5(8):2271-7.

Supplemental Content

Loading ...
Support Center